Imatinib (IM), a competitive inhibitor capable to bind to the ATP pocket in the kinase domain of BCR-ABL1 protein, was the first TKI used in CML therapy, with over 95% of response rates [20,21]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.